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AbstrAct
Objective Survival and causes of death (COD) in 
multiple sclerosis (MS) provide ultimate endpoints. We 
aimed to investigate survival and COD in a 60-year 
population-based MS cohort compared with the general 
population.
Methods All patients with incident multiple sclerosis 
(MS) (N=1388) with onset during 1953–2012 in 
Hordaland County, Western Norway, were included. 
Data were obtained from patient records at Haukeland 
University Hospital and linked to the Norwegian COD 
registry. Survival adjusted for sex, age and disease course 
were estimated by Kaplan-Meier analyses from birth and 
from disease onset. Mortality and COD in MS relative to 
the general population were examined by standardised 
mortality ratio (SMR).
results Of 1388 patients, 291 had deceased, mainly of 
MS (56.4%). Median life expectancy was 74.7 years for 
MS and 81.8 years for the general population (p<0.001); 
77.2 years for women with MS and 72.2 years for men 
with MS (p<0.001). Life expectancy for patients with 
relapsing remitting MS (RRMS) was 77.8 years and  
 71.4 years for primary progressive MS (PPMS) (p<0.001). 
Overall SMR was 2.7 (p>0.0001); 2.9 in women and 
2.5 in men (p=0.0009). SMR was 2.4 in RRMS and 3.9 
in PPMS (p<0.0001). SMR from disease onset during 
1953–1974 was 3.1; 2.6 during 1975–1996 and 0.7 
during 1997–2012 (p<0.0083). No difference in cause-
specific deaths were found (p=0.0871).
conclusion We found a 7-year shorter life expectancy 
and almost threefold higher mortality in MS compared 
with the general population. A rise in survival in MS was 
observed during the entire observation period.
IntrOductIOn
Longitudinal studies have revealed a promising 
change in longevity prognosis in multiple sclerosis 
(MS) with increased life expectancies in MS over 
the last decades.1–4 Similar survival trends have been 
seen also in the general population, questioning 
whether the gap in survival incidence between MS 
and the general population has changed over time.5 
Patients with MS, on average, have shortened life 
expectancies by 7–14 years.4–7 Gender inequality 
for standardised mortality ratio (SMR) in disfa-
vour of females has been reported despite a slower 
disability progression rate reported among women 
with MS and a longer life expectancy.8 9 In terms 
of disease course and mortality, a higher mortality 
rate among patients with primary progressive MS 
(PPMS) has been shown with respect to patients 
with relapsing-remitting MS (RRMS).2 4 MS, as 
noted on the death certificates has been reported 
as the the most common cause of death (COD) 
in patients with MS, and this trend has remained 
stable over time.2 7 10
COD analyses are important to quantify the 
nature and magnitude of underlying diseases, 
and, where possible, to compare COD in MS 
with COD in matched reference subjects. Here, 
we present results based on an observation time 
of  60 years on MS survival and cause-specific 
mortality, the longest follow-up study reported 
to date. This population-based study included all 
patients with incident MS in Hordaland County, 
Western Norway. Our main objective was to 
determine life expectancy in MS and to identify 
a potential change in survival between patients 
with MS and the general population during the 
observation period. Second, we aimed to compare 
mortality rates of cause-specific deaths in MS to 
the matched general population.
MethOds
settings and study design
All patients with onset of MS during 1953–2012 
in Hordaland County were included in the study. 
Patient’s identification was obtained from patient 
records at the Departments of Neurology at Hauke-
land University Hospital and Haugesund Hospital, 
the only departments of neurology in Hordaland 
county, Western Norway. Additional records for 
patients with optic neuritis at the department of 
Ophthalmology, Haukeland University Hospital, 
were evaluated. For several decades, repeated 
surveys of MS epidemiology have been performed 
in these departments to maintain a continuous over-
sight and update of MS incidence and prevalence 
data.11 Patients were diagnosed as having definite or 
probable MS according to the criteria of Poser until 
1 January 2001 and according to McDonald diag-
nostic criteria from 2001 and revised McDonald 
criteria (2010).12–14 Year of birth, age and age at 
onset (first clinical symptom) and at diagnosis, 
gender, disease course at onset (RRMS and PPMS), 
time period (year) for onset and diagnosis and COD 
were registered. Patient records were linked to the 
COD Registry at Statistics Norway for obtaining 
date and COD, classified according to the Interna-
tional Classification of Diseases (ICD-6, ICD-10). 
We used all entries recorded on the death certificates 
to ensure inclusion of all COD. However, only the 
primary COD was used in the sensitivity analysis, 
as all other causes were insufficiently recorded. The 
follow-up period ended 31 December 2012.
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Expected life expectancy for the general Norwegian popula-
tion according to age, gender and calendar year was based on 
yearly population mortality tables obtained from The Human 
Mortality Data Base (http://www. mortality. org/ Public/ Cita-
tionGuidelines. php).
The study was approved by the Regional Committee for 
Medical Research Ethics in Western Norway.
statistical analysis
Descriptive methods were used to characterise the sample (demo-
graphic and clinic properties) The Fisher’s exact test was used 
to compare six categorical COD: MS, cardiovascular and cere-
brovascular diseases, cancer, respiratory and infectious diseases, 
accidents and suicide and others according to gender and disease 
courses RRMS and PPMS.15 Survival curves for the observed MS 
population and in MS subgroups (gender, disease course) were 
assessed by Kaplan-Meier (log-rank) both from birth and from 
disease onset and compared with the (expected) mortality in the 
general Norwegian population.
The mortality rates for MS, MS subgroups (gender, initial 
disease course), age at onset and diagnosis, time period for 
onset and diagnosis and COD were compared with the general 
Norwegian population and assessed by SMRs.16 The SMR is the 
ratio of the observed patient mortality to the mortality for the 
general Norwegian population (expected) corresponding to age, 
gender and calendar year.16
All computation has been done in R.17
results
demographic and clinical data
Table 1 displays a total of 1388 patients with MS identified, 533 
(38%) men and 855 (62%) women. Of these, 1209 (87%) patients 
were diagnosed with RRMS and 179 (13%) with PPMS. By 31 
December 2012, a total of 291 (21%) patients had died. Of these, 
131 (45%) were men and 160 (55%) were women.
survival and all-cause mortality analyses
All Kaplan-Meier survival analyses are shown in figure 1A-H, 
found statistical significant differences at the level of p<0.001. 
Median life expectancy for all patients with MS was 74.7 years, 
compared with 81.8 years in the general population (figure 1A). 
Median survival from disease onset of MS was 40.6 years 
compared with 54.6 years in the general population (figure 1B). 
Men with MS had a median life expectancy of 72.2 years 
compared with 78.9 years among men in the general population 
(figure 1C). Median survival age from MS onset for men was  35.7 
years compared with 49.6 years for men in the general popula-
tion (figure 1D). Women with MS had a median life expectancy 
of 77.2 years, compared with 84.6 years among women in the 
general population (figure 1E). From onset, women with MS 
had a median life span of 42.6 years compared with 55.6 years 
for women in the general population (figure 1F). Patients with 
RRMS had longer life expectancy (77.8 years) than patients with 
PPMS (71.4 years) (figure 1G). In RRMS, median survival from 
table 1 Observed and expected number of deaths and standardised mortality ratios (SMR) by gender, disease course and periods for disease at 
onset, period for diagnosis, age at onset and age at diagnosis for patients with multiple sclerosis (MS) in Hordaland
Group n Observed, n (%) expected, n (%) sMr (95 % cI) p-value (log-rank)
All patients 1388 291 (21.0) 107.3 (7.7) 2.7 2.4 to 3.0 <0.0001
Gender 0.0009
  Male 533 131 (24.6) 52.6 (9.9) 2.5 2.1 to 2.9
  Female 855 160 (18.7) 54.7 (6.4) 2.9 2.5 to 3.4
Course of disease at onset <0.0001
  RRMS 1209 202 (16.7) 84.4 (7.0) 2.4 2.1 to 2.7
  PPMS 179 89 (49.7) 23.0 (12.8) 3.9 3.1 to 4.7
Period for onset 0.0083
  1953–1974 237 155 (65.4) 49.8 (21.0) 3.1 2.6 to 3.6
  1975–1996 638 130 (20.4) 49.4 (7.7) 2.6 2.2 to 3.1
  1997–2012 513 6 (1.1) 8.1 (1.6) 0.7 0.3 to 1.5
Period for diagnosis <0.0001
  1953–1974 136 100 (73.5) 33.4 (24.6) 3 2.5 to 3.6
  1975–1996 602 178 (29.6) 58.3 (9.7) 3.1 2.6 to 3.5
  1997–2012 650 13 (2.0) 15.7 (2.4) 0.8 0.5 to 1.4
Age at onset (years) <0.0001
  20 107 20 (18.7) 2.7 (2.5) 7.3 4.5 to 10.9
  21–30 471 90 (19.1) 22.3 (4.7) 4 3.3 to 4.9
  31–40 459 90 (19.6) 35.2 (7.7) 2.6 2.1 to 3.1
  41–50 246 61 (13.4) 28.2 (6.2) 2.2 1.7 to 2.8
  51–60 92 25 (27.2) 15.0 (16.3) 1.7 1.1 to 2.4
  61+ 13 5 (38.5) 3.9 (3.0) 1.3 0.5 to 2.8
Age at diagnosis (years) 0.0043
  20 49 6 (12.2) 0. 7 (1.4) 9 3.6 to 18.3
  21–30 327 57 (17.4) 10.6 (3.2) 5.4 4.1 to 6.9
  31–40 454 90 (19.8) 25.5 (5.6) 3.5 2.9 to 4.3
  41–50 356 81 (22.8) 37.0 (10.4) 2.2 1.7 to 2.7
  51–60 161 42 (26.1) 24.3 (15.1) 1.7 1.3 to 2.3
  61+ 41 15 (36.6) 9.2 (22.4) 1.6 0.9 to 2.6
PPMS, primary progressive MS; RRMS, relapsing-remitting MS.
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onset was 42.8 years, compared with 25.5 years for patients with 
PPMS (figure 1H).
Data on mortality of all causes showed an overall SMR of 
2.7 in MS compared with the general population (p<0.0001). 
SMR was 2.4 in RRMS and 3.9 in PPMS (p<0.0001) (table 1). 
In women, SMR was 2.9 and SMR was 2.5 in men (p=0.0009). 
SMR was 3.1 for disease onset during 1953–1974, 2.6 for 
disease onset during 1975–1996 and 0.7 for disease onset 
during 1997–2012 (p=0.0083) (table 1). Similar significant 
differences were observed for SMRs for analyses from the year 
of diagnosis; SMR was 3.0 for diagnosis during 1953–1974, 
3.1 during 1975–1996 and 0.8 during 1997–2012 (p<0.0001). 
SMRs for 10-year intervals of age at disease onset were gradually 
reduced from 7.3 for those with disease onset before 20 years 
of age to 1.3 for those with onset above 60 years (p<0.0001) 
(table 1). Similar significant reduction were recorded for SMRs 
for 10–year intervals of age at diagnosis; SMR was 9.0 for diag-
nosis before 20 years of age and 1.6 for diagnosis after 60 years 
(p=0.0043) (table 1).
cause of death
Table 2 displays the frequencies of causes of death in MS 
according to gender and disease courses and the mortality rate of 
cause-specific deaths between patients with MS and the matched 
general population. The main COD noted on the death certifi-
cates (immediate COD) was MS in 56.4% (n=164) of patients 
with MS. For all six CODs, no gender (p=0.35) or course specific 
(p=0.49) trends in death distribution were found. Cardiovas-
cular and cerebrovascular diseases and cancer were in addition 
to MS most frequent, accounting for 14.8% (n=43) and 14.1% 
(n=41), respectively. Respiratory and infectious causes were 
recorded in 3.8% (n=11), accidents and suicide in 4.5% (n=13) 
and unknown cause was reported in 6.5% (n=19). There was 
no significant difference in SMR for all cause-specific deaths in 
MS compared with the general population (p=0.0871) (table 2).
dIscussIOn
In this 60-year incidence-based population cohort from Western 
Norway, we demonstrated a median reduction in life expectancy 
Figure 1 Kaplan-Meier survival curves of patients with multiple sclerosis (MS) in Hordaland county from birth (left column: A, C, e, G) and from disease 
onset (right column: B, D, F, H). A, B: Patients with MS versus the general population of Norway. e, F: Women with MS versus women in the general 
population of Norway. C, D: Men with MS versus men in the general population of Norway. G, H: RRMS versus PPMS. PPMS, primary progressive MS; RRMS, 
relapsing-remitting MS.
table 2 Observed and expected number of causes of death and SMR for MS patients in Hordaland County and the general Norwegian population 
with onset during 1953–2012
Immediate cause of death* n
Observed, 
n (%) expected, n (%) sMr 95% cI
p Value 
(log rank) Men, n (%)
Women,  




MS 164 164 (56.3) 14.8 (34.1)** 11.1 9.5 to 12.9 69 (52.7) 95 (59.4) 114 (56.4) 50 (56.2)
Cardiovascular and 
cerebrovascular diseases
43 43 (14.8) 13.1 (30.2) 3.3 2.4 to 4.4 23 (17.6) 20 (12.5) 25 (12.4) 18 (20.2)
Cancer 41 41 (14.1) 7.6 (17.6) 5.4 3.9 to 7.2 18 (13.7) 23 (14.4) 32 (15.8) 9 (10.1)
Respiratory and infectious 
diseases
11 11 (3.8) 2.4 (5.5) 4.5 2.3 to 7.7 8 (6.1) 3 (1.8) 8 (4.0) 3 (3.4)
Accidents and suicide 13 13 (4.4) 1.4 (3.2) 9.6 5.3 to 15.8 5 (3.8) 8 (5.0) 10 (4.9) 3 (3.4)
Other diseases 19 19 (6.5) 4 (9.2) 4.8 2.9 to 7.2 8 (6.1) 11 (6.9) 13 (6.4) 6 (6.7)
Total 291 291 (100) 43.3 (100) 131 (100) 160 (100) 202 (100) 89 (100)
*International Classification of Diseases (ICD) codes: sixth and seventh editions for deaths before 1969; 8 hour edition for deaths in 1969–1992; ninth edition for deaths in 
1993–1998; 10 hours edition for deaths after 1 January 1999.
**All causes of death.
PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SMR, standardised mortality ratio.
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of 7.1 years and overall an almost threefold increase in mortality 
rate in MS compared with the matched general population.
Our findings correspond to previous reports of MS mortality, 
and recent reports of 6–6.5 years survival reduction in similar 
studies in Canada and Spain.2 4 18 The median survival from 
disease onset was 41 years in MS, this is more than twice as long 
as reported in the first study on the topic in 1969 (17 years), 
reflecting a time trend towards a strong increase in life expectancy.4 
19 Similar to others, we also found that patients with younger age at 
onset had a higher relative risk of dying (higher SMR) than patients 
with an older age at onset.2 4 Women with MS had 5-year longer 
life expectancy (77.2 years) than men with MS (72.2 years) irre-
spective of measured from birth or from disease onset. The same 
5-year gender age difference in life expectancy was found in the 
general population, indicating that the longer survival age found in 
women with MS reflects the longer survival age found in women 
in the general population. In our study, the SMR for women (2.9) 
was significantly higher than for men (2.5), confirming data from 
previous studies.7 9 A Swedish nationwide study found an increased 
risk of heart failure and stroke in women with MS, similar to a 
previous Danish report.7 20 Women with PPMS have also been 
reported to have an increased hazard compared with men with 
PPMS.4 If women with MS truly have an increased mortality risk 
compared with men, further studies designed to investigate such a 
difference are, therefore, warranted. Global cardiovascular risk in 
MS, estimated by the Framingham Cardiovascular Risk Score, has 
recently been associated with increased MS disability and disease 
progression.21 With regards to investigating gender differences in 
mortality, added insight into the impact of gender-linked disparities 
in cardiovascular and lifestyle risk factors as well as treatment strat-
egies and biological disease mechanisms would be warranted.20 22
Life expectancy has increased enormously in the general 
population during the 20th century.23 In most European coun-
tries, the life expectancy at birth was around 50 years in the 
early 1900s and has increased to approximately 75 years for men 
and 81 years for women in the year of 2000.23 One important 
reason for this improved survival has been the marked decline 
in cardiovascular diseases in advanced ages observed during the 
last decades.24 Multiple other factors have also likely contributed 
to this shift, such as general improvement in healthcare, better 
disability rehabilitation, socioeconomic development, better 
treatment for comorbid disorders, medical advances and lifestyle 
changes (smoking, diet, exercise, use of alcohol). In particular, 
the observed decline in smoking since the 1970–1980s have had 
a favourable impact on life expectancy.25
According to disease course in MS, we found that patients 
with RRMS outlived patients with PPMS by almost 7 years 
from birth, and the mortality risk (SMR) was twofold higher in 
PPMS compared with in RRMS. Consistent with our results, two 
previous studies reported similar observations.4 5 On the other 
hand, they found similar survival ages in RRMS and in PPMS, 
which was different from the findings of our study.
Whether the increased life expectancy and lower mortality 
rate in RRMS is/was influenced by the availability of efficient 
disease modifying treatments for RRMS as opposed to in PPMS 
is currently unknown.26 27
Analyses of COD patterns show that MS was the leading 
COD in more than half of cases, in line with existing data.2 7 
18 27 However, no significant differences regarding the number 
of cause-specific deaths were observed between genders or 
disease courses. Also, when estimating the mortality (SMR) 
of cause-specific deaths no significant differences were found 
between the two populations. However, these results are 
probably influenced by the limited sample size in each cate-
gory of listed causes of deaths.
The main strength of our study was the long duration of 
follow-up of a population-based incidence cohort, which 
increases the likelihood of the measured outcome to occur, as 
well as completeness and validity of data. The long period of 
observation also improves both quantity and quality of data 
on competing risks, as health problems can manifest them-
selves at all stages in life, although the occurrence of health 
issues more commonly increase with ageing. The main limita-
tion of our study was the limited number of participants. Other 
limitations were mainly confined to the lack of information 
on lifestyle factors and comorbidities. The use of CODs based 
solely on death certificates have some limitations. The physi-
cians responsible for filling out the death certificate forms are 
in many instances not the patient’s primary care physician and 
may lack relevant clinical information on the patients medical 
history. There is variation in coding practices and in accuracy in 
identification of COD.28 Moreover, COD listed on death certif-
icates have shown discrepancies to the main diagnosis given at 
hospital discharge in patients who had been hospitalised during 
their final year of life and are also rarely autopsy confirmed.29 
The time lag from onset to diagnosis of MS have decreased over 
recent years, hence, the incidence rates of MS at the beginning 
of this study might also have been underestimated. The study 
is a population-based study comprising all patients with disease 
onset during the study period and may include fewer benign 
cases in the first decades and more such cases in the latest years. 
However, since MS usually lead to increased disability with time, 
benign cases in the first decades were probably diagnosed later 
and included in the 60-year follow-up, limiting this possible 
bias. Improved diagnostic tools and diagnostic criteria as well 
as advancement in general healthcare have made earlier diag-
nosis of MS possible, factors that potentially could play a role 
in the observed improvement in MS survival in recent decades. 
However, our results are compatible with most previous studies 
in showing improved life expectancy in MS over time. Thus, 
indicating a probable effect from increasingly effective MS ther-
apies and improved overall MS care, leading to reduction in 
complications from MS in advanced disease stages.30
When estimating the overall SMR during this 60-year 
follow-up time, a nearly threefold higher mortality rate in MS 
compared with the general population was recorded.9 Yet, irre-
spective of SMRs being measured from onset or from diagnosis, 
an overall significant increase in survival in MS compared with 
the general population was observed during the entire 60-year 
follow-up period. However, in the most recent time period 
(1997–2012), which showed a similar SMR (0.7) to the general 
population, the patients were in their early adulthood, and this 
SMR result should, therefore, be interpreted with uttermost 
caution. We studied the natural course of MS, and the availability 
of disease modifying therapies from mid-1990s could likely not 
have influenced our results. Also, incomplete treatment data and 
heterogeneous treatment strategies would have caused biases on 
treatment effect, if analysed. However, recent findings from a 
pivotal trial of the first available therapy of interferon beta 1b, 
showed a decreased mortality in the active treatment arm  21 
years later.31 The rapid development of new disease therapies 
in MS and overall improved caretaking of the disabled during 
the last decades are thus promising for future improvements of 
survival and life expectancy in MS.
However, to estimate future trends in life expectancy more 
accurately, it is crucial to facilitate and take advantage of MS 
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registries with detailed information on the use of disease modi-
fying treatment as well as comorbidities and lifestyle factors.
correction notice Since this paper was first published online there have changes 
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